PMID- 14750243
OWN - NLM
STAT- MEDLINE
DCOM- 20040210
LR  - 20141120
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 121
IP  - 1
DP  - 2004 Jan
TI  - Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas 
      comparing HercepTest and PathVysion FISH assay.
PG  - 70-7
AB  - We evaluated and compared 2 HER-2 tests (immunohistochemical analysis 
      [HercepTest, DAKO, Carpinteria, CA] and fluorescence in situ hybridization 
      [FISH]) and assessed chromosome 17 polysomy status in relation to these tests. 
      HER-2 status was obtained in 690 cases. The rinse step in the HercepTest before 
      and after addition of the visualization reagent was 2 minutes in 188 cases and 
      was increased to 5 minutes in 600 cases. HercepTest with both rinse steps was 
      performed on duplicate slides in 98 cases. Chromosome 17 ploidy status based on 
      FISH results was determined in 687 cases. Weak overexpression (2+) of HER-2 
      protein was not due to gene amplification in a majority of cases (67/76 [88%]). A 
      small subset of breast carcinomas (19/687 [2.8%]) strongly overexpressed (3+) 
      HER-2 protein without gene amplification. The aneuploidy rate was similar in 
      negative and 2+ cases (60/141 [42.5%] and 12/26 [46%]), compared with 86% (18/21) 
      in 3+ cases. The incidence of polysomy 17 in 2+ nonamplified cases (3/67 [4%]) 
      was similar to that seen in negative cases (5.5%), in contrast with 47% (9/19) of 
      3+ nonamplified cases. Adding a longer rinse step to the HercepTest converted a 
      subset (3/10 [30%]) of weakly positive cases to negative cases. Weak 
      overexpression of HER-2 protein in a majority of cases seems to represent an 
      artifactual staining pattern. Chromosome 17 polysomy is a major factor in strong 
      HER-2 protein overexpression in 3+ nonamplified cases.
FAU - Varshney, Dolly
AU  - Varshney D
AD  - Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los 
      Angeles, CA, USA.
FAU - Zhou, Yvonne Y
AU  - Zhou YY
FAU - Geller, Stephen A
AU  - Geller SA
FAU - Alsabeh, Randa
AU  - Alsabeh R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Reagent Kits, Diagnostic)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Aneuploidy
MH  - Breast Neoplasms/*genetics/metabolism/pathology
MH  - Carcinoma/*genetics/metabolism/pathology
MH  - *Chromosomes, Human, Pair 17
MH  - DNA, Neoplasm/analysis
MH  - Female
MH  - Flow Cytometry
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Reagent Kits, Diagnostic
MH  - Receptor, ErbB-2/*genetics/metabolism
EDAT- 2004/01/31 05:00
MHDA- 2004/02/11 05:00
CRDT- 2004/01/31 05:00
PHST- 2004/01/31 05:00 [pubmed]
PHST- 2004/02/11 05:00 [medline]
PHST- 2004/01/31 05:00 [entrez]
AID - 10.1309/FUQH-92B0-3902-5LHG [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2004 Jan;121(1):70-7. doi: 10.1309/FUQH-92B0-3902-5LHG.